Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Journal of the National Cancer Institute
|
August 3, 2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO
Jacobus Pfisterer, Béatrice Weber, Alexander Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancer
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J Davis, Karen E Sheppard, Michael S Anglesio, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
Annals of Surgical Oncology
|
November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Rüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Journal of the National Cancer Institute
|
August 3, 2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO
Jacobus Pfisterer, Béatrice Weber, Alexander Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Florian Heitz, Stefan Kommoss, Roshan Tourani, et al.
The Lancet. Oncology
|
June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancer
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
Molecular Cancer Therapeutics
|
April 9, 2015
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J Davis, Karen E Sheppard, Michael S Anglesio, et al.
Cancers
|
March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2017
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss, Boris Winterhoff, Ann L Oberg, et al.
Annals of Surgical Oncology
|
November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Rüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
Page
of 10